Allied-Market-Research-mobile

Coming Up With New Logo

Cart
0
Get 20% Free Customization In This Report

Liquid Biopsy Market by Product & Service (Reagents, Instruments, and Service), Cancer Type (Lung, Breast, Colorectal, Prostate, Liver, and Others), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [CtDNA], and Other Biomarkers) - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: LI 171891
  • Apr 2017
  • 164 pages
  • Price: $4296
$2765

Liquid Biopsy Market Overview:

Global Liquid Biopsy Market was valued at $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023. Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. It is a non-invasive blood test that could provide researchers, physicians, and surgeons with information about the cancer profile of the patient and appropriate therapy to improve the survival rate of the cancer patients. It is a rapid process that usually includes a simple blood draw, extraction of nucleic acids from the blood plasma, and amplification of the molecular targets to permit analysis of the defined biomarkers. Easy and non-invasive access to the tumor genome, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients. The advantages of liquid biopsy over solid tumor biopsy, rise in awareness about minimally invasive procedures, favorable government initiatives, and presence of huge cancer population base are major factors that drive the market growth.

The global liquid biopsy market is segmented based on product & service, circulating biomarker, cancer type, end user, and geography. Based on product & service, it is categorized into reagents, instruments and services. On the basis of circulating biomarker, it is classified into circulating tumor cells, circulating tumor DNA, extracellular vesicles and other biomarkers. The market is studied across different cancer types, such as lung, breast, colorectal, prostate, liver, and other cancers. Based on end user, it is bifurcated into hospitals & laboratories and government & academic research centers. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The market is expected to witness a moderate growth during the forecast period, owing to the benefits offered by liquid biopsies over solid tissue biopsy methods. Furthermore, surge in prevalence of cancer and rise in awareness about minimally invasive methods among the patient pool are anticipated to augment the market growth. The increase in pre-screening programs for cancer detection is expected to present various opportunities for market expansion. However, alternatives to liquid biopsies and unclear reimbursement & regulation scenario are expected to hamper the market growth.

The report provides extensive competitive analysis and profiles of key market players, such as Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Myriad Genetics, Janssen Diagnostics, LLC., Trovagene Inc., Guardant Health Inc., GRAIL, and MDX Health SA.

The other players in the value chain include Fraunhofer-Gesellschaft, Horizon Discovery, Illumina, Inc., Cynvenio, Diagnologix, Exosome Sciences, and CyoTrack.

Asia-Pacific possesses high market potential for the growth of liquid biopsy market, owing to high incidence of cancer and rise in healthcare expenditure. This region is anticipated to experience fast-paced growth, in terms of development and use of liquid biopsy tests.

India liquid biopsy market is projected to grow at a CAGR of 32.7% during the forecast period.

Key Benefits

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on geography assists to understand the regional market and the strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Liquid Biopsy Market Key Segments

By Product & Service

  • Reagents
  • Instruments
  • Services

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Other Cancers

By Circulating Biomarker

  • Circulating Tumor Cells
  • Extracellular Vesicles
  • Circulating Tumor DNA
  • Other Biomarkers

By End User

  • Hospitals & Laboratories
  • Government & Academic Research Centers

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. REGULATIONS
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Increase in demand for safe and non-invasive procedures
3.6.1.2. Surge in the global prevalence rate of cancer
3.6.1.3. Advantages of liquid biopsy tests over traditional tests

3.6.2. Restraints

3.6.2.1. Limitations associated with liquid biopsy testing
3.6.2.2. Lack of awareness in developing and underdeveloped regions

3.6.3. Opportunities

3.6.3.1. Use of liquid biopsy for treatment of rare cancer
3.6.3.2. Untapped potential of emerging markets

Chapter: 4 LIQUID BIOPSY MARKET,  BY PRODUCT & SERVICE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. KITS & REAGENTS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. PLATFORMS & INSTRUMENTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. SERVICES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 LIQUID BIOPSY MARKET,  BY CIRCULATING BIOMARKER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. CIRCULATING TUMOR CELL (CTC)

5.2.1. Market size and forecast

5.3. CIRCULATING TUMOR DNA (CTDNA)

5.3.1. Market size and forecast

5.4. EXTRACELLULAR VESICLES (EVS)

5.4.1. Market size and forecast

5.5. OTHER BIOMARKERS

5.5.1. Market size and forecast

Chapter: 6 LIQUID BIOPSY MARKET,  BY CANCER TYPE

6.1. OVERVIEW

6.1.1. Market Size and Forecast

6.2. LUNG CANCER

6.2.1. Market size and forecast

6.3. BREAST CANCER

6.3.1. Market size and forecast

6.4. COLORECTAL CANCER

6.4.1. Market size and forecast

6.5. PROSTATE CANCER

6.5.1. Market size and forecast

6.6. LIVER CANCER

6.6.1. Market size and forecast

6.7. OTHER CANCERS

6.7.1. Market size and forecast

Chapter: 7 LIQUID BIOPSY MARKET,  BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. HOSPITAL AND LABORATORY

7.2.1. Market size and forecast

7.3. GOVERNMENT AND ACADEMIC RESEARCH CENTERS

7.3.1. Market size and forecast

Chapter: 8 LIQUID BIOPSY MARKET,  BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Canada market size and forecast
8.2.3.3. Mexico market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. Germany market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. UK market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. Australia market size and forecast
8.4.3.4. India market size and forecast
8.4.3.5. South Korea market size and forecast
8.4.3.6. Taiwan market size and forecast
8.4.3.7. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Turkey market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

Chapter: 9 COMPANY PROFILES

9.1. BIOCEPT, INC.

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Product portfolio
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. BIO-RAD LABORATORIES, INC.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments

9.3. F. HOFFMANN-LA ROCHE AG

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments

9.4. GUARDANT HEALTH, INC.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Key strategic moves and developments

9.5. ILLUMINA, INC.

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6. JOHNSON & JOHNSON

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance

9.7. MDXHEALTH SA

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. MYRIAD GENETICS, INC.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments

9.9. QIAGEN N.V.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments

9.10. TROVAGENE, INC.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Product portfolio
9.10.4. Business performance
9.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 2. KITS & REAGENTS BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 3. PLATFORMS & INSTRUMENTS LIQUID BIOPSY MARKET, BY GEOGRAPHY,  2016-2023 ($MILLION)
TABLE 4. SERVICE LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 5. GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 6. GLOBAL CTC LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. CTDNA LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 8. EVS LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. OTHER BIOMARKERS LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 11. LUNG CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 12. BREAST CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. COLORECTAL CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 14. PROSTATE CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. LIQUID BIOPSY LIVER CANCER MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 16. LIQUID BIOPSY OTHER CANCERS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 17. GLOBAL LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 18. HOSPITAL AND LABORATORY LIQUID BIOPSY MARKET, BY GEOGRAPHY,  2016-2023 ($MILLION)
TABLE 19. GOVERNMENT AND ACADEMIC RESEARCH CENTER LIQUID BIOPSY MARKET,  BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 20. LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 21. NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,  2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 26. EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 28. EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 29. EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 30. EUROPE LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER,  2016-2023 ($MILLION)
TABLE 34. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 35. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 36. LAMEA LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 38. LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 39. LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 40. LAMEA LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 41. BIOCEPT INC.: COMPANY SNAPSHOT
TABLE 42. BIOCEPT INC.: PRODUCT PORTFOLIO
TABLE 43. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 44. BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 45. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 46. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 47. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENT
TABLE 48. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 49. GUARDANT HEALTH INC.: COMPANY SNAPSHOT
TABLE 50. GUARDANT: PRODUCT CATEGORY
TABLE 51. ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 52. ILLUMINA, INC.: OPERATING SEGMENTS
TABLE 53. ILLUMINA, INC.: PRODUCT PORTFOLIO
TABLE 54. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 55. JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 56. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 57. MDXHEALTH SA: COMPANY SNAPSHOT
TABLE 58. MDXHEALTH SA: PRODUCT CATEGORIES
TABLE 59. MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
TABLE 60. MYRIAD GENETICS, INC.: OPERATING SEGMENTS
TABLE 61. MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO
TABLE 62. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 63. QIAGEN N.V.: OPERATING SEGMENTS
TABLE 64. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 65. TROVAGENE, INC. : COMPANY SNAPSHOT
TABLE 66. TROVAGENE, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GLOBAL LIQUID BIOPSY MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL LIQUID BIOPSY MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE AND DISTRIBUTION
FIGURE 4. GLOBAL LIQUID BIOPSY MARKET: TOP PLAYER POSITIONING
FIGURE 5. BARGAINING POWER OF BUYERS
FIGURE 6. BARGAINING POWER OF SUPPLIERS
FIGURE 7. THREAT OF NEW ENTRANTS
FIGURE 8. THREAT OF SUBSTITUTION
FIGURE 9. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SEGMENTATION, BY CIRCULATING BIOMARKER
FIGURE 11. U.S. LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 12. CANADA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 13. MEXICO LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 14. GERMANY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 15. FRANCE LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 17. ITALY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 18. SPAIN LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 19. REST OF EUROPE LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 20. JAPAN LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 21. CHINA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 22. AUSTRALIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 23. INDIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 24. SOUTH KOREA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 25. TAIWAN LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 28. TURKEY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 29. SAUDI ARABIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 32. BIOCEPT INC.: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. BIO-RAD LABORATORIES, INC.: NET SALES, 2014-2016 ($MILLION)
FIGURE 34. BIO-RAD LABORATORIES, INC.: REVENUE BY SEGMENT, 2016 (%)
FIGURE 35. BIO-RAD LABORATORIES, INC.: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 36. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2014-2016 ($MILLION)
FIGURE 37. F. HOFFMANN-LA ROCHE LTD.: REVENUE BY SEGMENT, 2016 (%)
FIGURE 38. F. HOFFMANN-LA ROCHE LTD.: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 39. ILLUMINA, INC.: NET SALES, 2014-2016 ($MILLION)
FIGURE 40. ILLUMINA, INC.: REVENUE BY PRODUCT, 2016 (%)
FIGURE 41. ILLUMINA, INC.: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 42. JOHNSON & JOHNSON: NET SALES, 2014-2016 ($MILLION)
FIGURE 43. JOHNSON & JOHNSON: REVENUE BY SEGMENT, 2016 (%)
FIGURE 44. JOHNSON & JOHNSON: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 45. MDXHEALTH SA: NET SALES, 2014-2016 ($MILLION)
FIGURE 46. MYRIAD GENETICS, INC.: NET SALES, 2014-2016 ($MILLION)
FIGURE 47. MYRIAD GENETICS, INC.: REVENUE BY PRODUCT, 2016 (%)
FIGURE 48. QIAGEN N.V.: NET SALES, 2014-2016 ($MILLION)
FIGURE 49. QIAGEN N.V.: REVENUE BY CUSTOMER CLASS, 2016 (%)
FIGURE 50. QIAGEN N.V.: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 51. TROVAGENE, INC.: NET SALES, 2014-2016 ($MILLION)

 

Liquid biopsy tests have gained popularity as an efficient, non-invasive alternative to solid tissue biopsies for cancer treatment. At present, liquid biopsy tests are used for molecular and diagnostic characterization of tumor fragments and agents, such as circulating biomarkers (circulating tumor cells, circulating tumor DNA, extracellular vesicles, and others), released in the blood of cancer patients. These tests are anticipated to manage & treat patients with rare cancers and help improve their survival rates in the near future. Moreover, improved diagnostic testing, increase in awareness among the population regarding cancer, and surge in pre-screening programs for cancer detection are further anticipated to provide growth opportunities and increase the adoption rate of these tests.

Rise in the number of cancer cases has led to an increase in the number of therapies to treat cancer, resulting in rise to the need for prognostic and diagnostic tests, especially liquid biopsies. Liquid biopsy tests serve this purpose by predicting the best approach for cancer treatment, understand the molecular characteristics of the cancer, predict the probability of cancer recurrence, and improve the patient stratification and real-time monitoring of therapies. Increasing number of healthcare professionals has preferred these tests to choose the appropriate cancer therapy and understand the onset of the disease. Liquid biopsies are expected to help improve the patient survival rate and reduce the cost of treatment for cancer patients, owing to the aid provided in prediction of the drug therapeutic targets.

The employment of liquid biopsies is highest in North America, owing to the increase in adoption of this test in the region, higher awareness about the benefits among the healthcare providers, and increase in disposable income among patients. Although, the use of liquid biopsies in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase, owing to rise in disposable income and government initiatives in the developing countries, such as China and India, to improve the care provided to the patients and contribute toward market growth.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 

Get More Information About This Report

For any queries about purchasing this report, For any queries, please fill the form below:

Please input the above text in the input box or click refresh

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASK
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts